ERASMID

Erasca, Inc.

HealthcareBiotechnology
$15.08
$0.00(-2.22%)
52W$1.21
$24.28
Updated Jun 22, 02:00 AM
RSI54
RS Rating97/99
Beta0.98
Volatility104%
F-Score3/9
Mkt Cap$4.7B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Erasca, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings contraction of 445% provides fundamental context to the price action. Investors should exercise caution due to high volatility (104% annualized), which requires wider risk management.

Relative Strength
97
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.98
vs S&P 500
MARKET
52W Position
60%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$13.72
50 SMA > 100 SMA$13.80
100 SMA > 150 SMA$10.78
150 SMA > 200 SMA$8.62

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$13.21+14.15%ABOVE
50 SMA$13.72+9.89%ABOVE
100 SMA$13.80+9.27%ABOVE
150 SMA$10.78+39.94%ABOVE
200 SMA$8.62+75.01%ABOVE

Price Performance

1D-2.2%
1W-2.4%
1M+33.1%
3M+1.3%
6M+279.7%
YTD+280.8%
1Y+8.8%
3Y+66.5%
52-Week Trading Range60% from low
$15.08
52W Low$1.21
52W High$24.28

Technical Indicators

RSI (14)NEUTRAL
53.6
305070
Setup ScoreCOOL
5/10
Base depth: 114.0%

Risk Profile

Beta
0.98
52W Vol
104%
ATR
$1.18
Max DD (1Y)
-59%

Volume Analysis

Today
8.34M
50D Avg
6.97M
Vol Ratio
1.20x
Liquidity
LIQUID

Earnings Momentum

Q2'25+59%
$-0.12
Q3'25
$-0.11
Q4'25+9%
$-0.10
Q1'26-445%
$-0.60
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:
5 Years:
3 Years:
TTM:

Compounded Profit Growth

10 Years:
5 Years:
3 Years:
TTM:-50.00%

Stock Price CAGR

10 Years:-2.40%
5 Years:-4.74%
3 Years:+66.53%
1 Year:+8.76%

Return on Equity

10Y Avg:-71.2%
5Y Avg:-42.1%
3Y Avg:-37.1%
Last Year:-77.0%

Key Metrics

Market Cap$4.7B
Gross Margin
Net Margin
Piotroski F-Score3/9

Frequently Asked Questions

Is ERAS in an uptrend right now?

ERAS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is ERAS overbought or oversold?

ERAS's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.

Is ERAS outperforming the market?

ERAS has a Relative Strength (RS) Rating of 97 out of 99. Yes, ERAS is a market leader, outperforming 97% of all stocks over the past 12 months.

Where is ERAS in its 52-week range?

ERAS is trading at $15.08, which is 62% of its 52-week high ($24.28) and 60% above its 52-week low ($1.21).

How volatile is ERAS?

ERAS has a Beta of 0.98 and 52-week volatility of 104%. It's less volatile than the S&P 500 - generally more stable.

Disclaimer: Data is for informational purposes only. May be delayed or contain errors. Past performance does not guarantee future results. This is not financial advice. Always conduct your own research and consult professionals before making investment decisions.